HUE043108T2 - (5,6-dihidro)pirimido[4,5-e]indolizinek - Google Patents

(5,6-dihidro)pirimido[4,5-e]indolizinek

Info

Publication number
HUE043108T2
HUE043108T2 HUE15712912A HUE15712912A HUE043108T2 HU E043108 T2 HUE043108 T2 HU E043108T2 HU E15712912 A HUE15712912 A HU E15712912A HU E15712912 A HUE15712912 A HU E15712912A HU E043108 T2 HUE043108 T2 HU E043108T2
Authority
HU
Hungary
Prior art keywords
indolizines
pyrimido
dihydro
Prior art date
Application number
HUE15712912A
Other languages
English (en)
Hungarian (hu)
Inventor
Man Adrianus Petrus Antonius De
Rogier Christian Buijsman
Jan Gerard Sterrenburg
Joost Cornelis Marinus Uitdehaag
Wit Joeri Johannes Petrus De
Guido Jenny Rudolf Zaman
Original Assignee
Netherlands Translational Res Center B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Translational Res Center B V filed Critical Netherlands Translational Res Center B V
Publication of HUE043108T2 publication Critical patent/HUE043108T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE15712912A 2014-04-07 2015-03-30 (5,6-dihidro)pirimido[4,5-e]indolizinek HUE043108T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP15153207 2015-01-30

Publications (1)

Publication Number Publication Date
HUE043108T2 true HUE043108T2 (hu) 2019-07-29

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15712912A HUE043108T2 (hu) 2014-04-07 2015-03-30 (5,6-dihidro)pirimido[4,5-e]indolizinek

Country Status (16)

Country Link
US (3) USRE50082E1 (enExample)
EP (1) EP3129374B1 (enExample)
JP (1) JP6518690B2 (enExample)
KR (1) KR102432420B1 (enExample)
CN (1) CN106132963B (enExample)
AU (1) AU2015243694B2 (enExample)
BR (1) BR112016022342B1 (enExample)
CA (1) CA2944610C (enExample)
DK (1) DK3129374T3 (enExample)
ES (1) ES2716165T3 (enExample)
HU (1) HUE043108T2 (enExample)
MX (1) MX368767B (enExample)
PL (1) PL3129374T3 (enExample)
PT (1) PT3129374T (enExample)
RU (1) RU2692479C2 (enExample)
WO (1) WO2015155042A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944610C (en) * 2014-04-07 2024-01-09 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
WO2016166255A1 (en) 2015-04-17 2016-10-20 Netherlands Translational Research Center B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
EP3416964B1 (en) * 2016-02-19 2020-12-16 Phoenix Molecular Designs 6-oxo-n-(1-(benzyl)-1h-pyrazol-4-yl)-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[1,2-a]pyrazine-2-carboxamide derivatives as p90 ribosomal s6 kinase (rsk) inhibitors for treating cancer
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
TWI664175B (zh) 2017-03-23 2019-07-01 大陸商北京加科思新藥研發有限公司 用於作為shp2抑制劑之新穎雜環衍生物
WO2020063760A1 (en) 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
EP3924352A4 (en) 2019-02-11 2022-11-16 Phoenix Molecular Designs CRYSTALLINE FORMS OF AN RSK INHIBITOR
MX2024007451A (es) * 2021-12-15 2024-07-09 Sillajen Inc Metodos de tratamiento de enfermedades neoplasicas.
MX2024007450A (es) * 2021-12-15 2024-07-04 Sillajen Inc Combinaciones farmaceuticas para utilizarse en el tratamiento de enfermedades neoplasicas.
KR20240096905A (ko) * 2021-12-15 2024-06-26 신라젠(주) 변형된 베타-사이클로덱스트린을 포함하는 약제학적 조성물
MX2024010802A (es) * 2022-03-04 2024-09-11 Sillajen Inc Combinaciones farmaceuticas para uso en el tratamiento de enfermedades neoplasicas.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160915A0 (en) * 2001-09-19 2004-08-31 Aventis Pharma Sa Indolizines inhibiting kinase proteins
DK1636236T3 (da) 2003-05-22 2013-12-09 Nerviano Medical Sciences Srl Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
US8207180B2 (en) 2006-11-28 2012-06-26 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
JP5542133B2 (ja) * 2008-06-26 2014-07-09 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ピラゾロ−キナゾリン
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
ES2660146T3 (es) 2009-04-29 2018-03-21 Nerviano Medical Sciences S.R.L. Sales del inhibidor de cdk
JP5851990B2 (ja) 2009-07-29 2016-02-03 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｐｌｋ阻害剤の塩
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
WO2012080229A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
BR112013018515B1 (pt) * 2011-01-26 2021-06-29 Nerviano Medical Sciences S.R.I Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase
AU2014302710B2 (en) 2013-06-24 2018-10-04 Merck Patent Gmbh Imidazole compounds as modulators of FSHR and uses thereof
CA2944610C (en) * 2014-04-07 2024-01-09 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines

Also Published As

Publication number Publication date
CN106132963A (zh) 2016-11-16
KR102432420B1 (ko) 2022-08-17
MX2016012997A (es) 2016-12-07
USRE48974E1 (en) 2022-03-15
US9856258B2 (en) 2018-01-02
EP3129374B1 (en) 2018-12-19
RU2692479C2 (ru) 2019-06-25
EP3129374A1 (en) 2017-02-15
JP2017510595A (ja) 2017-04-13
BR112016022342B1 (pt) 2022-10-04
ES2716165T3 (es) 2019-06-10
USRE50082E1 (en) 2024-08-20
RU2016141405A (ru) 2018-05-07
CN106132963B (zh) 2019-08-06
MX368767B (es) 2019-10-15
AU2015243694A1 (en) 2016-11-03
AU2015243694B2 (en) 2019-01-17
CA2944610C (en) 2024-01-09
PT3129374T (pt) 2019-03-25
RU2016141405A3 (enExample) 2018-10-02
CA2944610A1 (en) 2015-10-15
KR20170013866A (ko) 2017-02-07
BR112016022342A2 (pt) 2017-08-15
PL3129374T3 (pl) 2019-07-31
BR112016022342A8 (pt) 2021-07-20
DK3129374T3 (en) 2019-04-08
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
JP6518690B2 (ja) 2019-05-22

Similar Documents

Publication Publication Date Title
PT3129374T (pt) (5,6-dihidro)pirimido[4,5-e] indolizinas
IL259169A (en) Novel pyrazolo pyrimidine derivatives
ZA201705802B (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
IL252053A0 (en) Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
ZA201802842B (en) [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
ZA201506570B (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
IL250823A0 (en) A new derivative of 6,5-dihydro-h4-benzo[b]thiano-[3,2-d]azepine
IL254167A0 (en) Combinations containing modified 3,2-dihydroimidazo[2,1-c]quinazoline
IL243092A0 (en) New triazolo[d–4,5]pyrimidine histories
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
IL262673A (en) A pyrazolo[5,1-a]pyrimidine compound
IL257413A (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
ZA201804619B (en) 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
EP3272627A4 (en) Multi-purpose vehicle
EP3190111A4 (en) Pyrazolo[3,4-c]pyridine derivatives
PT3119782T (pt) Compostos de 2,7-diazaspiro[3.5]nonano
GB201522532D0 (en) Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
IL250350A0 (en) History of tetrahydropyrrolo[4,3–][d3,1]thiazine as a BACE inhibitor
EP3227292A4 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
GB2553716B (en) Pyrrolopyrimidines as antitumor agents
HK1240222A1 (en) 4h-pyrido[1,2-a]pyrimidin-4-one compounds
AU2014904868A0 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
ZA201801639B (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
TH1601001194A (th) อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่